Provided by Tiger Trade Technology Pte. Ltd.

Alto Neuroscience Inc

24.56
+0.53002.21%
Volume:241.27K
Turnover:5.95M
Market Cap:954.66M
PE:-10.31
High:25.07
Open:23.81
Low:23.81
Close:24.03
52wk High:37.48
52wk Low:5.23
Shares:38.87M
Float Shares:29.65M
Volume Ratio:0.71
T/O Rate:0.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3816
EPS(LYR):-2.1918
ROE:-49.17%
ROA:-26.79%
PB:4.35
PE(LYR):-11.21

Loading ...

Alto Neuroscience Is Maintained at Outperform by Baird

Dow Jones
·
May 19

JonesTrading Keeps Their Buy Rating on Alto Neuroscience, Inc. (ANRO)

TIPRANKS
·
May 15

Alto Neuroscience price target raised to $24 from $21 at Wedbush

TIPRANKS
·
May 15

Alto Neuroscience Is Maintained at Neutral by Wedbush

Dow Jones
·
May 14

Alto Neuroscience: Buy Rating Reiterated as Lead Asset Advances and Cash Runway Extends; $28 Price Target Maintained

TIPRANKS
·
May 14

Alto Neuroscience Shareholders Shape Governance and Equity Plans

TIPRANKS
·
May 14

Alto Neuroscience shareholders approved amended 2024 employee stock purchase plan

Reuters
·
May 14

Wedbush Lifts Price Target on Alto Neuroscience to $24 From $21, Maintains Neutral Rating

MT Newswires Live
·
May 13

Sector Update: Healthcare Stocks Lean Lower Pre-Bell Wednesday

MT Newswires Live
·
May 13

Alto Neuroscience publishes corporate presentation on precision psychiatry, biomarker-driven brain drug pipeline

Reuters
·
May 13

Alto Neuroscience Q1 EPS $(0.80) Misses $(0.54) Estimate

Benzinga Earnings
·
May 13

Earnings Flash (ANRO) Alto Neuroscience Posts Q1 Loss $0.80 a Share, vs. FactSet Est of $0.56 Loss

MT Newswires Live
·
May 13

Alto Neuroscience initiates Phase 2b trial of ALTO-207 in treatment-resistant depression

Reuters
·
May 13

Alto Neuroscience Q1 FY26 net loss widens to $26.2 million; R&D expenses more than doubled to $20.3 million

Reuters
·
May 13

Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights

THOMSON REUTERS
·
May 13

Alto Neuroscience Inc Q1 EPS $-0.80

THOMSON REUTERS
·
May 13

Alto Neuroscience to present at Bank of America Securities Healthcare Conference

Reuters
·
May 12

Alto Neuroscience Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
May 12

Analysts Conflicted on These Healthcare Names: Ginkgo Bioworks Holdings (DNA), Xencor (XNCR) and Alto Neuroscience, Inc. (ANRO)

TIPRANKS
·
May 11

Alto Neuroscience presents Phase 2a data for ALTO-207 in MDD

TIPRANKS
·
May 04